Advancing scientific knowledge
Our Company
Driven by our dedication to improving outcomes in difficult-to-treat cancers, we are leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.
Our Science
Advancing antibody drug conjugates with a novel class of PBD dimers
Our Pipeline
A robust pipeline of investigational ADCs for the treatment of hematological cancers and solid tumors
Our Trials
Take a closer look at the LOTIS study designs
Recent Data
Explore the latest research from our scientists
Limited duration loncastuximab with rituximab induces high complete response rate in high-risk relapsed/refractory follicular lymphoma – A phase 2 study
ASH, 2023
Independent Ivestigator-Initiated Trial
Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ASH, 2023
Loncastuximab Tesirine Demonstrated Substantial Single-agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
ASH, 2023
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
(Glo-BNHL)
ASH, 2023
Independent
A Phase II Study of Loncastuximab Tesirine As Consolidation Strategy in Patients with LBCL in PR at Day 30 after CAR T-Cell Therapy.
ASH, 2023
Independent Ivestigator-Initiated Trial
Targeted DNA Damage Boost with Loncastuximab Tesirine in Combination with PARP Inhibitors in Diffuse Large B-Cell Lymphoma.
ASH
Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases
ASH, 2023
Clinical Quantitative Systems Pharmacology Framework Describing Loncastuximab Tesirine Distribution & to Explore Patient Outcomes from the LOTIS-2 Clinical Trial in Patients With B-Cell Lymphomas
ACCP, Sept 10-12 2023
Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
SOHO, 2023
LOTIS-5, an Ongoing Phase 3 Randomized Study of Loncastuximab Tesirine with Rituximab (Lonca-R) Versus Immunochemotherapy in Patients with R/R DLBCL
ICML, 2023
TIP Update
Long-Term Responses with Loncastuximab Tesirine: Updated Results From LOTIS-2, the Pivotal Phase 2 Study In Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
EHA, 2023
Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7)
ASCO, 2023
Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2
AACR, 2023
Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers
AACR, 2023
A phase 1/2 randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas
AACR, 2023
Independent
Discovery of plasma protein biomarkers associated with overall survival in R/R DLBCL patients treated with loncastuximab tesirine
AACR, 2023
CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling
ASH, 2022
A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)
ASH, 2022
Real-World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in US
ASH, 2022
Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of Therapy
ASH, 2022
Identification of Predictive Biomarkers for Response of R/R DLBCL Patients Treated with Loncastuximab Tesirine Using Low Pass Whole-Genome Sequencing (WGS)
ASH, 2022
Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
ASH, 2022
CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
ASH, 2022
Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties
ASH, 2022
ADCT-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial
ASH, 2022
Independent
A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)
ASH, 2022
Online Publication Only
MedConnect
Real-time answers to your pressing questions
Connect live with
Medical Affairs
Our Company
Driven by our dedication to improving outcomes in difficult-to-treat cancers, we are leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.
Read and download our brochure
Our Science
Advancing antibody drug conjugates with a novel class of PBD dimersADC Therapeutics’ proprietary ADCs are highly targeted drug constructs that combine monoclonal antibodies specific to surface tumor targets with a novel class of highly potent PBD-dimer toxins.PBD dimers do not distort the DNA structure, which makes them invisible to repair mechanisms and allows the cross-links to persist within the DNA.
Unlike earlier generation PBD chemistry, ADC Therapeutics’ proprietary PBD dimers are not a substrate for multi-drug resistance proteins—even in hard-to-treat tumors.Our PBD-dimer technology: A novel approach to hematologic cancers and solid tumors
-
1The antibody drug conjugate (ADC) binds to a specific tumor cell surface antigen and is internalized1,2
-
2The potent pyrrolobenzodiazepine (PBD) dimer toxin is released inside the cell, where it then creates a covalent cross-link between the strands of the DNA double helix2,3
-
3Because these cross-links do not distort the DNA structure, it is hypothesized that they remain invisible to repair mechanisms and can covertly persist to interrupt cell division and cause tumor cell death1-3
Watch an MOA video about our first approved ADC, loncastuximab tesirine-lpyl (2:32)
Our Pipeline
A robust pipeline of investigational ADCs for the treatment of hematological cancers and solid tumorsADCT has multiple PBD-based ADCs in ongoing clinical trials and numerous preclinical ADCs in development.Some of the agents represented in this pipeline chart are investigational. Efficacy and safety have not yet been established.
* LOTIS-6 trial currently on holdExpand each compound to learn more.
LONCASTUXIMAB TESIRINE-lpyl
Loncastuximab tesirine-lpyl is an ADC composed of a humanized monoclonal antibody that binds to human CD19 and is conjugated through a linker to a PBD–dimer toxin. CD19 is a clinically validated target for the treatment of B-cell malignancies.
adct-602
ADCT-602 is an ADC composed of a monoclonal antibody that binds to CD22 conjugated to a PBD-dimer toxin. CD22 is highly expressed on most malignant B-cells, including expression in more than 90% of patients with B-cell acute lymphoblastic leukemia (ALL). ADCT-602 is being evaluated in a phase I/II clinical trial in patients with relapsed or refractory B-cell ALL.
Hematology Franchise Clinical Trial
adct-601
ADCT-601 is an ADC composed of a humanized monoclonal antibody that binds to human AXL (licensed from BerGenBio), conjugated using Glycoconnect™ technology (licensed from Synaffix BV) to a linker with a PBD-dimer toxin. AXL is highly overexpressed in many solid tumors and hematological malignancies. ADCT-601 is being evaluated in a phase 1 clinical trial in patients with selected advanced solid tumors.
adct-901
ADCT-901 is an ADC composed of a humanized monoclonal antibody (3A4) directed against human KAAG1 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD–dimer cytotoxin. KAAG1 has high expression in tumors with high unmet medical need, while its expression on healthy tissue is very restricted. ADCT-901 is being developed for the treatment of advanced solid tumors with high unmet medical needs, including platinum resistant ovarian cancer and triple negative breast cancer.
Solid Tumor Franchise Clinical
Trial
Trial
Our Trials
Take a closer look at the LOTIS study designs
Recent Data
Explore the latest research from our scientists
Limited duration loncastuximab with rituximab induces high complete response rate in high-risk relapsed/refractory follicular lymphoma – A phase 2 studyASH, 2023
Independent Ivestigator-Initiated Trial
View Abstract
Independent Ivestigator-Initiated Trial
View Abstract
Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell LymphomaASH, 2023
View Abstract
View Abstract
Loncastuximab Tesirine Demonstrated Substantial Single-agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)ASH, 2023
View Abstract
View Abstract
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL)ASH, 2023
Independent
View Abstract
Independent
View Abstract
A Phase II Study of Loncastuximab Tesirine As Consolidation Strategy in Patients with LBCL in PR at Day 30 after CAR T-Cell Therapy.ASH, 2023
Independent Ivestigator-Initiated Trial
View Abstract
Independent Ivestigator-Initiated Trial
View Abstract
Targeted DNA Damage Boost with Loncastuximab Tesirine in Combination with PARP Inhibitors in Diffuse Large B-Cell Lymphoma.ASH
View Abstract
View Abstract
Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic DiseasesASH, 2023
View Abstract
View Abstract
Clinical Quantitative Systems Pharmacology Framework Describing Loncastuximab Tesirine Distribution & to Explore Patient Outcomes from the LOTIS-2 Clinical Trial in Patients With B-Cell LymphomasACCP, Sept 10-12 2023View Abstract
Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCLSOHO, 2023View Abstract
LOTIS-5, an Ongoing Phase 3 Randomized Study of Loncastuximab Tesirine with Rituximab (Lonca-R) Versus Immunochemotherapy in Patients with R/R DLBCLICML, 2023
TIP UpdateView Abstract
TIP UpdateView Abstract
Long-Term Responses with Loncastuximab Tesirine: Updated Results From LOTIS-2, the Pivotal Phase 2 Study In Patients with Relapsed/Refractory Diffuse Large B-Cell LymphomaEHA, 2023View Abstract
Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7)ASCO, 2023View Abstract
Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2AACR, 2023View Abstract
Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancersAACR, 2023View Abstract
A phase 1/2 randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomasAACR, 2023
IndependentView Abstract
IndependentView Abstract
Discovery of plasma protein biomarkers associated with overall survival in R/R DLBCL patients treated with loncastuximab tesirineAACR, 2023View Abstract
CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology ModelingASH, 2022View Abstract
A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)ASH, 2022View Abstract
Real-World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in USASH, 2022View Abstract
Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of TherapyASH, 2022View Abstract
Identification of Predictive Biomarkers for Response of R/R DLBCL Patients Treated with Loncastuximab Tesirine Using Low Pass Whole-Genome Sequencing (WGS)ASH, 2022View Abstract
Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)ASH, 2022View Abstract
CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin LymphomaASH, 2022View Abstract
Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic PropertiesASH, 2022View Abstract
ADCT-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 TrialASH, 2022
IndependentView Abstract
IndependentView Abstract
A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)ASH, 2022
Online Publication OnlyView Abstract
Online Publication OnlyView Abstract
